Eli M. Wallace's most recent trade in BridgeBio Oncology Therapeutics Inc. was a trade of 1,114,400 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc | Eli M. Wallace | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 1,114,400 | 1,114,400 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Oncology Therapeutics Inc | Eli M. Wallace | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Dec 2025 | 1,114,400 | 500,000 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Oncology Therapeutics Inc | Eli M. Wallace | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2025 | 1,614,400 | 1,614,400 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Oncology Therapeutics Inc | Eli M. Wallace | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 499,731 | 499,731 | - | - | Stock Option (Right to Buy) |